Funder
Bundesministerium für Bildung und Forschung
Deutsche Forschungsgemeinschaft
Publisher
Springer Science and Business Media LLC
Reference77 articles.
1. Roskoski, R. The erbb/her family of protein-tyrosine kinases and cancer. Pharmacological Research 79, 34–74 (2014).
2. Baselga, J., Norton, L., Albanell, J., Kim, Y. M. & Mendelsohn, J. Recombinant humanized anti-her2 antibody (herceptin (tm)) enhances the antitumor activity of paclitaxel and doxorubicin against her2/neu overexpressing human breast cancer xenografts. Cancer Research 58, 2825–2831 (1998).
3. Chen, D.-H. & Zhang, X.-S. Targeted therapy: resistance and re-sensitization. Chinese Journal of Cancer 34, 43 (2015).
4. Mimeault, M., Hauke, R., Mehta, P. P. & Batra, S. K. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. Journal of Cellular and Molecular Medicine 11, 981–1011 (2007).
5. Carvalho, S., Levi-Schaffer, F., Sela, M. & Yarden, Y. Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: Iuphar review 18. British Journal of Pharmacology 173, 1407–1424 (2016).
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献